Equities

Ascendis Pharma A/S

Ascendis Pharma A/S

Actions
  • Price (EUR)117.00
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024 18:31 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of EUR
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments399735682
Total Receivables, Net562623
Total Inventory20913175
Prepaid expenses393225
Other current assets, total------
Total current assets703923806
Property, plant & equipment, net111129126
Goodwill, net3.503.503.50
Intangibles, net0.921.331.78
Long term investments5.6930146
Note receivable - long term2.131.921.81
Other long term assets------
Total assets8261,0901,085
LIABILITIES
Accounts payable------
Accrued expenses------
Notes payable/short-term debt000
Current portion long-term debt/capital leases25257.00
Other current liabilities, total774534
Total current liabilities197171100
Total long term debt61948398
Total debt644508105
Deferred income tax5.83----
Minority interest------
Other liabilities, total1491722.96
Total liabilities971826201
SHAREHOLDERS EQUITY
Common stock2,1312,1212,115
Additional paid-in capital------
Retained earnings (accumulated deficit)(2277)(1860)(1214)
Treasury stock - common(0.15)(0.15)(22)
Unrealized gain (loss)------
Other equity, total0.723.453.78
Total equity(146)263884
Total liabilities & shareholders' equity8261,0901,085
Total common shares outstanding585757
Treasury shares - common primary issue--1.110.15
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.